3.38
-0.075(-2.17%)
Currency In GBp
Address
Pencoed Business Park
Pencoed, CF35 5HY
United Kingdom of Great Britain and Northern Ireland
Phone
44 20 3819 8400
Website
Sector
Healthcare
Industry
Biotechnology
Employees
26
First IPO Date
August 12, 2005
| Name | Title | Pay | Year Born |
| Dr. John David Sinden B.A., BA, M.A., MA, Ph.D. | Co-Founder | 103,000 | 1951 |
| Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D | Executive Chairman | 430,000 | 1954 |
| Mr. Simon Dew | Chief Business Officer | 0 | N/A |
| Ms. Suzanne Hancock | Chief Operations Officer | 0 | N/A |
| Dr. Randolph Corteling Ph.D. | Chief Scientific Officer | 0 | N/A |
| Mr. Hadley Chilton | Secretary | 0 | N/A |
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.